CardioSTAT can record up to 14 days of data with a compliance rate of 99.9%. Credit: Clker-Free-Vector-Images from Pixabay.

Canadian medical technology company Icentia has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its ambulatory, continuous electrocardiogram (ECG) monitoring solution called CardioSTAT.

The wire-free and single-use CardioSTAT recorder is a flexible, lightweight, and showerproof device, which can be easily worn on the upper chest for cardiac monitoring.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Icentia co-founder and CEO Pierre Paquet said: “This approval marks a key milestone for our company. The FDA clearance opens the door to the world’s largest medical device market.

“With the cost effectiveness and demonstrated ability of our cardiac monitoring solution to provide effective patient care and outcomes, we have no doubts that CardioSTAT will make a meaningful difference in the diagnosis of patients with cardiac disorders in the US.”

CardioSTAT has the potential to provide up to 14 days of continuous ECG recording and analysis  with a compliance rate of 99.9%.

See Also:

Offering multiple options in terms of monitoring durations ranging between 24 hours and 14 days, the device helps healthcare professionals address a wide range of clinical requirements through pay by duration model.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medical practitioners can use the device to detect difficult-to-identify heart anomalies, including atrial fibrillation.

The FDA clearance of the device will allow the company to expand its market to the US.

CardioSTAT is claimed to be among the leading wearable cardiac monitoring devices in Canada. The company expanded to the UK market in 2018. More than 170,000 devices have been distributed to date.                                                                                                                

Icentia, which is involved in the development of medical devices, has cardiac diagnostic testing facilities in Canada and the UK.